A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis Review


Authors: Haque, T.; Shastri, A.; Desai, P.; Xie, Z.; Hammond, D.; King, Z.; Kishtagari, A.; Madanat, Y. F.; Abaza, Y.; Silver, A. J.; Singh, A.; Borate, U. M.; Heimlich, J. B.; Slosky, D. A.; Bolton, K. L.; Patnaik, M. S.; Bick, A. G.; Verma, A. K.; Jaiswal, S.; Steensma, D. P.; Savona, M. R.
Review Title: A blueprint for pursuing therapeutic interventions and early phase clinical trials in clonal haematopoiesis
Abstract: The age-associated mutational state of clonal haematopoiesis (CH) is linked to multiple adverse health outcomes. As higher risk CH can lead to progressive neoplastic or vascular disease, there is interest in developing clinical trials to mitigate risk associated with CH. Given the high prevalence of CH, data from clinical trials could have broad public health implications for screening and therapy. Thoughtful consideration is needed to design trials that are both clinically relevant and avoid overmedicalization. Here, we summarize clinical studies of CH to date and provide suggestions and guidance on how to approach designing CH-focused therapeutic clinical trials. These recommendations are derived from discussions among clinical researchers and scientists emanating from the Inaugural Meeting on Somatic Mutations and Predisease in October 2021. © 2024 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Keywords: somatic mutation; review; prevalence; drug development; drug therapy; cytopenia; therapy; clinical trials; vascular disease; clonal hematopoiesis; human; clonal cytopenias; overmedicalization
Journal Title: British Journal of Haematology
Volume: 206
Issue: 2
ISSN: 0007-1048
Publisher: John Wiley & Sons  
Date Published: 2025-02-01
Start Page: 416
End Page: 427
Language: English
DOI: 10.1111/bjh.19925
PUBMED: 39653653
PROVIDER: scopus
PMCID: PMC11829135
DOI/URL:
Notes: Review -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Tamanna Haque
    9 Haque